Takeda

Global Contract Manufacturing of Pharmaceuticals

New Post-Hoc Analyses Extend Understanding of the Efficacy and Safety of Lurasidone in the Treatment of Schizophrenia

Takeda

Takeda Pharmaceuticals International and Sunovion Pharmaceuticals has announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda (lurasidone) in patients with schizophrenia at the 23rd European Congress of Psychiatry (EPA).

Download to find out more.

Available Downloads